Albany, NY -- (SBWIRE) -- 06/24/2019 -- Post-Cardiac Arrest Syndrome Market Insights, Epidemiology and Market Forecast-2028
1. There were approximately 1,150,165 diagnosed incident cases of sudden cardiac arrest in 2016 in 7 major markets.
2. In 2016, 103,374 sudden cardiac arrest cases have gained a return of the spontaneous circulation (ROSC) out of which 77,530 were ROSC-Comatose cases at the time of hospital admission in the United States.
3. In 2016, the incident cases of IHSCA (In Hospital Sudden Cardiac Arrest) and OHSCA (Out of Hospital Sudden Cardiac Arrest) in Japan was found to be 72,117 and 123,000. These incident cases are further expected to increase by 2027.
DelveInsight launched a new report on Post-Cardiac Arrest Syndrome Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Post-Cardiac Arrest Syndrome market report covers a descriptive overview and comprehensive insight of the Post-Cardiac Arrest Syndrome epidemiology and Post-Cardiac Arrest Syndrome market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Post-Cardiac Arrest Syndrome market report provides insights on the current and emerging therapies.
3. Post-Cardiac Arrest Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Post-Cardiac Arrest Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Post-Cardiac Arrest Syndrome market.
Request for sample pages
"Among the European countries, Germany had the highest diagnosed incident cases of Sudden Cardiac Arrest with 148,438 cases, followed by the United Kingdom which had diagnosed incident."
Post-Cardiac Arrest Syndrome Market analysis carried out for the period of 2016-2027 demonstrates that Post-Cardiac Arrest Syndrome Market size will grow and was found out to be USD 547.0 Million in 2016 in seven major markets. The United States accounts for the largest Post-Cardiac Arrest Syndrome market size in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. At present, there is no therapy approved for the Post-Cardiac Arrest Syndrome treatment/prevention and the current standard of neuroprotection is targeted temperature management and controlled Oxygenation. The current treatment approach has shown good results in many cases but still unable to reduce the mortality incidences. NeuroproteXeon/Mallinckrodt is developing Xenon gas as add-on therapy with the current standard of neuroprotectants to counter the post-cardiac arrest brain injury associated mortality.
The current standard of Post-Cardiac Arrest Syndrome treatment for neuroprotection is controlled mechanical ventilation and targeted temperature management. This approach has shown good results in many cases but the survival to hospital discharge rate for victims after successful ROSC is still disappointing. Many neuroprotectants are being explored at different levels following numerous target and mechanisms of action such as NMDA antagonist, Inhibition of glutamate release, Anti- apoptosis, buffering of metabolic acidosis, anti-inflammatory, increased oxidative stress, attenuation of oxidative and inflammatory injury, inhibition of reactive oxygen species, reversible inhibition of mitochondrial complex I, improved organ perfusion, decrease intracranial pressure and decrease brain edema. Either most of these therapies are in a preclinical stage or failed to show significant benefit than Xenon gas therapy by NeuroproteXeon/Mallinckrodt.
The Food and Drug Administration (FDA) has granted Fast Track designation to xenon gas for inhalation for use in Post-Cardiac Arrest Syndrome patients. Also, the company has a Special Protocol Agreement with the FDA and a Scientific Working Party Agreement with the European Medicines Agency (EMA).
Companies across the globe are working towards the development of Post-Cardiac Arrest Syndrome treatment therapies like:-
1. NeuroproteXeon
2. Mallinckrodt
and many others
Drugs in the clinical trials are expected to propel the growth of the Post-Cardiac Arrest Syndrome drugs market in the upcoming years are:-
1. Xenon
And many others
Table of contents
1. Key Insights
2. Post-Cardiac Arrest Syndrome Market Overview at a Glance
3. Post-Cardiac Arrest Syndrome Disease Overview
4. Post-Cardiac Arrest Syndrome Epidemiology and Patient Population
5. Post-Cardiac Arrest Syndrome Country Wise-Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Post-Cardiac Arrest Syndrome Current Treatment Practices
7. Post-Cardiac Arrest Syndrome Unmet Needs
8. Post-Cardiac Arrest Syndrome Emerging Therapies
8.1. Xenon: NeuroproteXeon/ Mallinckrodt
9. Post-Cardiac Arrest Syndrome 7 Major Market Analysis
10. Post-Cardiac Arrest Syndrome Market Outlook by Country
11. The United States: Market Outlook
11.1. United States Market Size
11.2. EU-5 Countries: Market Outlook
11.3. Germany Market Size
11.4. France Market Size
11.5. Italy Market Size
11.6. The United Kingdom Market Size
11.7. Spain Market Size
11.8. Japan: Market Outlook
11.9. Japan Market Size
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight